多发性骨髓瘤患者血清炎症因子的变化及其临床意义

Changes of Serum Levels of Inflammatory Factors in Multiple Myeloma and Their Clinical Significances

目的探讨多发性骨髓瘤(MM)患者血清炎症因子的变化及其临床意义。方法采用ELISA法测定150例多发性骨髓瘤患者(MM组)和50例正常体检者(对照组)血清白细胞介素-6(IL-6)及肿瘤坏死因子-α(TNF-α)水平,同时采用胶乳增强免疫透射比浊法检测两组患者血清高敏C-反应蛋白(hsCRP)水平,并分析各指标间相关性。结果MM组血清IL-6、TNF-α和hsCRP水平明显高于对照组,且随临床分期增加依次增高,差异有统计学意义(P<0.01)。MM患者血清中IL-6与hsCRP呈正相关(γ=0.546,P<0.01),与TNF-α亦呈正相关(γ=0.711,P<0.01),TNF-α与hsCRP呈正相关(γ=0.568,P<0.01);与治疗前相比,MM治疗有效组血清IL-6、TNF-α和hsCRP水平明显下降(P<0.01,t=9.770,3.448,18.390),而治疗无效组则差异无统计学意义(P>0.05)。结论血清炎症因子检测可用于MM患者的病情判断和疗效监测。

Objective To investigate the changes of serum levels of inilammatory factors in multiple myeloma （MM） and their clinical significances. Methods The ELISA method was employed to measure the serum levels of interleukin-6 （IL-6） and tumor necrosis factor-alpha （TNF-α） between 150 MM patients （MM group） and 50 healthy controls （control group）, and latex-enhanced immunity transmission turbidity method was used for the measurement of serum high-sensitivity C-reactive protein （hsCRP）. And the associations between above three indices were analyzed. Results The sermn levies of IL-6, TNF-α and hsCRP were markedly higher in the MM group than in the control group, and they were increased significantly with increasing clinical stage, demonstrating considerable differences between varying stages （P〈0.01）. In serum of MM patients, IL-6 was directly related to hsCRP （γ=0.546, P〈0.01） as well as TNF-α （T=0.711,P〈0.01）, and TNF-α positively correlated with hsCRP（γ=0.568,P〈0.01）. The serum levels of IL-6, TNF-α and hsCRP were substantially reduced in the groups of potent therapy for MM after treatment when compared with those before treatment, allP〈0.01 （t=9.770, 3.448, and 18.390 respectively）, while no significant alterations were noted before and after treatment in the group of ineffective therapy （P 〉 0.05）. Conclusion Measurement of the serum inflammatory factors aided in judging disease condition and monitoring their efficacies in MM patients.